<DOC>
	<DOCNO>NCT00551291</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety combination NeoRecormon , CellCept prednisone patient low moderate risk myelodysplastic syndrome ( MDS ) . In first phase study , patient receive CellCept ( 1g p.o . twice daily ) plus prednisone . After 3 month , patient respond treatment , NeoRecormon ( 30000 IU/week , s.c. ) add treatment regimen . If response NeoRecormon 6 week , dose increase 60000 IU/week . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study NeoRecormon ( Epoetin Beta ) , CellCept ( Mycophenolate Mofetil ) Prednisone Patients With Low Intermediate Myelodysplastic Syndromes .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; diagnosis MDS , accord International Prognostic Scoring System ( IPSS ) criterion ; low intermediate risk , candidate treatment growth factor , respond treatment . previous treatment CellCept , erythropoietinstimulating drug ; diagnosis proliferative chronic myelomonocytic leukemia ; prior concomitant malignancy MDS , exception basocellular , spinocellular adequately treat situ cervical cancer , past 3 year ; biological antitumor myelosuppressive treatment within 28 day start study ; bone marrow precursor cell transplantation previous study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>